Diabetes and Cardiovascular Disease:  The Well-Established Connection—A Debate Among Experts
 
 
CONTINUING MEDICAL EDUCATION INFORMATION
 
Release Date:  January 14, 2014
Last Reviewed: January 13, 2014
Expiration Date: January 14, 2015
Time to Complete Activity: 2.25 hours

*This activity expired for credit on January 14, 2015 and is no longer available for credit
 
This activity is sponsored by Global Education Group.
Paradigm Medical Communications, LLC is the educational partner.
 
FACULTY
 
Vivian Fonseca, MD
Professor of Medicine and Pharmacology
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, LA
 
Allison B. Goldfine, MD
Associate Professor
Harvard Medical School
Head, Section of Clinical Research
Joslin Diabetes Center
Boston, MA
 
Kieren J. Mather, MD
Professor of Medicine
Department of Medicine
Division of Endocrinology and Metabolism
Indiana University School of Medicine
Indianapolis, IN
 
Sanjay Rajagopalan, MD, FACC, FAHA
Chief, Division of Cardiovascular Medicine
University of Maryland, Baltimore
Baltimore, MD
 
TARGET AUDIENCE 
The target audience for this initiative includes experts in the areas of cardiology, internal medicine, primary care, endocrinology/diabetology, physician assistants, nurse practitioners, and other allied healthcare professionals interested in and actively engaged in the management of patients with diabetes.
 
STATEMENT OF NEED
Poorly controlled diabetes is a major risk factor for cardiovascular (CV) complications, and adults with diabetes are 2 to 4 times more likely than those without diabetes to suffer from heart disease or stroke. CV complications are the leading cause of death in patients with type 2 diabetes, with more than half of these patients dying from cardiovascular disease (CVD). Poor glycemic control can contribute to the development of CV risk. Many contributing factors are modifiable, making it incumbent upon the clinician to ensure that these are addressed properly and early so as to limit CV risk. The goal of this educational initiative is to educate clinicians on how to improve patient care by communicating the latest significant, comprehensive, evidence-based advances in the diagnosis and treatment of diabetes and to address the more important issue of diabetes with comorbid conditions such as CVD.
 
EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:
  • Explain how the evidence expressed in the ADA and AACE type 2 diabetes treatment algorithms supports the safe and effective application of personalized medicine in patients with type 2 diabetes.
  • Illustrate how long-term glucose control can be attained in various clinical settings, including in patients with diabetes and comorbid kidney impairment or cardiovascular comorbidities, by utilizing the different clinical characteristics of GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT2 inhibitors.
  • Describe the diverse effects on cardiovascular outcomes and risk markers associated with the various classes of antidiabetic drugs.
AGENDA
 
Introduction
 
5 minutes
Chapter 1
New Treatment Algorithms from the ADA and AACE
26 minutes
Chapter 2
Merging New and Old Agents: Finding Synergy for Optimal Patient Care
28 minutes
Chapter 3
Balancing Glycemic Control and Cardiovascular Protection
32 minutes
Chapter 4
Case Discussion/Q&A
22 minutes
 
FACULTY AND PLANNER DISCLOSURES
In accordance with Accreditation Council for Continuing Medical Education requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.
 
 Name of Faculty or Presenter
 Reported Financial Relationship
 Vivian Fonseca, MD
 Grant/Research Support: Abbott, Eli Lilly, Endo Barrier, NovoNordisk, Pan American
 Laboratories, Reata, Sanofi-Aventis
 Honoraria:Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi
 Sankyo, Eli Lilly, GlaxoSmithKline, NovoNordisk, Palmas, Sanofi-Aventis, Takeda
 Allison B. Goldfine, MD
 Consulting: FDA, Endocrine and Metabolic Drug Advisory Committee
 Grant/Research Support: ADA, Amneal Pharmaceutical, Caraco Pharmaceuticals,
 Daiichi Sankyo, Lifescan - a Division of Johnson and Johnson, Nestle, NIH, NovoNordisk
 Kieren J. Mather, MD
 
 Grant/Research Support: Merck, NIH, NovoNordisk, Roche, Sanofi
 Sanjay Rajagopalan, MD, FACC,
 FAHA
 Nothing to disclose
 
The planners and managers reported the following financial relationships or relationships:
 
Name of Planner or Manager
Reported Financial Relationship
 Ashley Marostica, RN, MSN
 Nothing to disclose
 Amanda Glazar, PhD
 Nothing to disclose
 
Paradigm Medical Communications, LLC staff members have no financial conflicts to disclose.
 
PHYSICIAN CONTINUING EDUCATION
Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
Credit Designation Statement
Global Education Group designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
NURSE PRACTITIONER CONTINUING EDUCATION

Global Education Group is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners (AANP): AANP Provider Number 11021. This program has been approved for 2.25 contact hours of continuing education (which includes 1.0 pharmacology hours).
 
This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standard.
 
PHYSICIAN ASSISTANT CONTINUING EDUCATION
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 2.25 hours of Category 1 credit for completing this program.
 
DISCLOSURE OF COMMERCIAL SUPPORT
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc., which was made possible, in part, through collaboration with Eli Lilly and Company.
 
INSTRUCTIONS FOR PARTICIPATION
To receive a CME certificate of participation, you should:
·         Follow instructions to register or log in with your professional information and complete the pretest.
·         View the online activity in its entirety.
·         Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the activity.
 
A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.
 
There is no fee required for participation in this activity.
 
HARDWARE/SOFTWARE REQUIREMENTS
This certified CME activity is designed as a self-running Flash presentation. In the event that you need this plug-in, a link to download the required Flash Player has been provided below.
 
Flash Player 10 or later required–download at http://www.adobe.com/support/flashplayer/downloads.html
 
For your convenience, a control bar is located at the bottom of the screen to move forward and backwards through the deck. Click the toggle button with the arrows to view the webinar in full screen. Press the Esc button on your keyboard while in full screen view to return to normal view, and to view the list of chapters.
 
Supported Browsers:
For Windows: Internet Explorer 7 or higher, Firefox 4.0, Safari 3, Google Chrome, Opera 9.5
For Mac: Safari 3, Firefox 4.0, Google Chrome
For Linux: Firefox 4.0
 
Technical Support: Technical Support: If you have any technical problems or playback issues, please send an email to: contactus@paradigmmc.com.
 
RESOLUTION OF CONFLICT OF INTEREST
Paradigm Medical Education, LLC (Paradigm) and Global Education Group (Global) require instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Paradigm and Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
 
© 2014 Paradigm Medical Communications, LLC, except where noted. This web presentation may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.
 
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Paradigm and Global do not recommend the use of any agent outside of the labeled indications. 
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 
CONTACT US
For information about the accreditation of this program, please contact Global at (303) 395-1782 or inquire@globaleducationgroup.com.